NANS 2026 Recap: From Last Resort to Precision Medicine

Tired of the same old pain management conversations? The North American Neuromodulation Society’s 2026 Annual Meeting delivered exactly what the doctor ordered.

Las Vegas, January 22-25. Neurosurgeons, pain specialists, orthopedic surgeons, engineers, and industry innovators gathered for a masterclass on where neuromodulation is headed. And trust us, it’s getting interesting.

Over 60 sessions packed into five days. A sprawling exhibit hall showcasing everything from next-gen electrode arrays to closed-loop systems that would make tech enthusiasts jealous. The 2026 meeting made one thing crystal clear: neuromodulation is precision medicine.

The Pre-Game Show

Before the main event even kicked off, NANS set the tone with seriously hands-on pre-conference offerings. Hands-on cadaver courses for neurosurgery and neurology residents? Check. Advanced implantation workshops for pain fellows? Also check. These weren’t your typical PowerPoint-based CME credit chasers. These were clinicians rolling up their sleeves to get anatomically intimate with spinal cord and brain implantation techniques. For early-career professionals, the message was clear: if you’re serious about neuromodulation, you need to know how to place these devices with precision.

The Big Questions Getting Bigger

Friday’s opening keynote, “Plenary I: Decoding the Mind: Trailblazing and Ethics in Brain-Computer Interfaces,” signaled that NANS wasn’t going to let the field get too caught up in the tech without stopping to ask the harder questions. 

What does it mean to decode the mind? Who gets access? How do we do this ethically? These questions threaded through multiple sessions, reflecting a maturing field that understands innovation without responsibility is just recklessness with FDA approval.

The Spine Wars (Spoiler: No Clear Winner)

One of the most revealing aspects? Watching the tension between traditional surgical approaches and interventional procedures play out in real time. The fact that orthopedic surgeons, neurosurgeons, and pain management physicians are increasingly collaborating on these discussions, rather than competing, suggests the field is maturing. The patient outcome, not professional turf, is becoming the driving force.

The Pain Evolution

Pain management sessions went well beyond the standard chronic low back pain lectures. Lectures like “Novel Neuromodulation Insights for an Old Problem: Advances in Treating Chronic Knee Pain.” Discussions around pelvic pain and complex facial pain conditions showed that practitioners are getting creative with indications.

The message: if it’s chronic, if it’s refractory, neuromodulation might be worth exploring.

One particularly intriguing session, “Emerging Concepts in Focused Ultrasound for Neuromodulation,” suggested the field isn’t resting on its electrode laurels. New modalities are coming. They’re going to force everyone to rethink what neuromodulation even means.

The Engineering Nerd Fest (In the Best Way)

For those who geek out on the technical side, NANS delivered in spades. “Beyond Conventional Pulses: Innovative Waveform Designs Across Neuromodulation Modalities” and “Macro vs. Micro: Debating the Optimal Electrode Size for Next-generation Neurostimulation” felt less like academic exercises and more like the conversations that shape device development over the next five years.

The discussions around wearable integration and closed-loop systems made it clear: the future of neuromodulation isn’t just about where you place the electrode. It’s about making the entire system smarter, more adaptive, and more personalized.

Industry players clearly got the memo. Innovation theaters throughout the meeting featured emerging companies like Nalu Medical and MicroTransponder alongside the traditional powerhouses, Boston Scientific, Medtronic, Abbott, and Stryker. The competitive landscape is heating up. That’s good news for clinicians who want options.

The Bottom Line

The 2026 NANS Annual Meeting reinforced what many in the field already sense: neuromodulation has moved beyond being a niche intervention for the “nothing else worked” crowd. It’s becoming a mainstream treatment option with expanding indications, evolving technology, and serious clinical evidence backing multiple applications.

For orthopedic surgeons considering adding neuromodulation to their toolkit, particularly for chronic pain and complex spine cases, the message was unmistakable: the field is mature, the evidence is growing, and the technology is advancing faster than most people realize.

For device manufacturers and industry professionals, the takeaway was equally clear: innovation is accelerating, competition is intensifying, and the clinicians in the room are demanding smarter, more adaptive, and more personalized solutions. The days of one-size-fits-all neuromodulation are over.

As the conference wrapped and attendees headed back to their respective practices, one thing was certain: neuromodulation isn’t slowing down. It’s only getting started.